|
|
 |
|
Viewing report
|
|
|
|
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs
Datamonitor, Dec 2003, Pages: 37
Introduction
Urinary incontinence can be defined as ‘the involuntary loss of urine which is objectively demonstrable and a social or hygienic problem’.
Within this broad definition, urinary incontinence in adults can be further classified into four main types of incontinence based on the symptoms experienced at presentation and the physiological characteristics associated with the disease.
These four main types of incontinence are: overflow incontinence, stress urinary incontinence, urge incontinence and mixed incontinence. Partly in a bid to increase the number and type of patients with incontinence eligible for clinical trials, the FDA has adopted an alternative term, 'overactive bladder', to describe a syndrome that encompasses not only urge incontinence, but also urgency, frequency, dysuria and nocturia. Detrol, Ditropan XL and Detrol LA are all approved in the US and Europe for the treatment of overactive bladder (OAB).
Pfizer’s aggressive marketing activity to support the launch of Detrol (tolterodine) also successfully raised wider disease awareness. With the two market leading drugs both suffering from poor side-effect profiles, and considerable scope for improved efficacy, there is still considerable unmet need in the market.
Scope
- Overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population
- Review of the performance of the leading drugs in the market, Pfizer’s Detrol (tolterodine) and ALZA’s Ditropan XL (oxybutynin chloride)
- Analysis of the potential of Yamanouchi’s Vesicare (solifenacin succinate), Novartis’s Enablex (darifenacin) and Eli Lilly’s duloxetine
Report Highlights
- Fighting off strong competition from Yamanouchi’s Vesicare and Enablex from Novartis, Pfizer’s Detrol will maintain its position as urinary incontinence market leader.
- Of the two drugs expected to launch in 2004, Vesicare is expected to prove more popular than Enablex, backed up by favorable results from a head-to-head study with Detrol. Thanks in part to this, its sales will surge to $971m by 2011 while Enablex will reach $743m.
- In the stress urinary incontinence sub-indication, Eli Lilly’s duloxetine will enjoy considerable success as the market expands, with sales of $488m forecast for 2011.
Reasons to Purchase
- Gauge the potential of the key late-stage pipeline products
- Understand the factors driving the urinary incontinence market
- Evaluate the patient potential in each of the key urinary incontinence sub-indications
Customers who bought this item also bought
Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Urinary Incontinence: Major Milestones
Strategic Perspectives 2002: CNS Disorders in Women - Urinary Incontinence
European Urinary Incontinence Therapeutics Markets
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Disease and Therapy Review: Urinary Incontinence
US market size for urinary incontinence drugs expressed as number of Detrol, Ditropan / Ditropan XL and oxybutinin / "other" prescriptions for 1987, 1999 and forecast for 2000 and 2004, with each UI drug's percent market share in 1987, 2000 and 2004
Trends and Developments in the European Urinary Incontinence
Target Product Profiles 2008: Physician Insights on Key Attributes - Urge Urinary Incontinence
Urinary Incontinence Devices Market: An Analysis
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies
|
|
|
|
